## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person * Elefant Dov					2. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [CLRB]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner					
(Last) (First) (Middle) C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 02/03/2020							X Officer (give title below) Other (specify below)  Chief Financial Officer					
(Street) FLORHAM, NJ 07932				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ Form	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqu							uired, Dis	ired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year	Exec any	2A. Deemed Execution Date, if any (Month/Day/Year		(Instr. 8)			(A) or Disposed of (D) (Instr. 3, 4 and 5)		of	Benefic	nt of Securities ally Owned Following Transaction(s) and 4)		Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							C	Code	V	Amou	or (D)	Price	÷			(I) (Instr. 4)	(IIIsu: 1)
Common stock 02/03/2020		02/03/2020				A		10,00	0 A	\$ 2.71	10,000	10,000		D			
Kemmuer.	Report on a s	reparate fine fo	r each class of secu Table II -	Deriva	ative Sec	curit	ies Ac	tquire	Perso conta the fo	ons whined in orm dis	no respo n this fo splays a	rm a curr neficia	re not rec ently vali	ection of in quired to re d OMB con	spond unle	ss	1474 (9-02)
1 Title of	12	3. Transaction		(e.g., p	4.							_		9 Dries of	9. Number	of 10.	11 Notur
Security	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Y	Execution Data	,	te, if Transaction Code (ear) (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		An Un Se	Title and nount of derlying curities str. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owners Form of Derivat Security Direct ( or Indir	Ownershi (Instr. 4) D)	
					Code	V	(A)		Date Exerc	isable	Expiratio Date	n Tit	Amour or Number of Shares				

#### **Reporting Owners**

		Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Elefant Dov C/O CELLECTAR BIOSCIENCES, INC 100 CAMPUS DRIVE FLORHAM, NJ 07932	2.		Chief Financial Officer					

### **Signatures**

/s/ Ch	ristina Blakley, attorney-in-fact for Dov Elefant	02/04/2020	
	**Signature of Reporting Person	Date	

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Common stock grant that vests in equal annual increments on February 3, 2021, February 3, 2022, and February 3, 2023.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.